绝经妇女MTHFR基因多态性与骨密度关系的meta分析

摘要

目的:采用meta分析方法研究绝经后妇女亚甲基四氢叶酸还原酶(MTHFR) C677T基因多态性与骨密度的关系.方法:通过多种数据库检索国内外已发表绝经妇女MTHFR基因多态性和骨密度关系的相关文章进行资料分析.结果:5篇文献符合meta分析纳入标准,均报道了绝经妇女MTHFR基因多态性与股骨颈和椎骨骨密度的关系.分析结果表明,TT基因型与CC/CT基因型妇女相比,具有更低的股骨颈密度,合并效应尺度(WMD)为-0.01g/cm2(95％ CI:-0.01～ 0.01,P＜0.001)；而TT基因型与CC/CT基因型妇女椎骨骨密度无差异,其WMD为-0.01mg/cm2(95％ CI:-0.04 ～0.01,P=0.32).结论:绝经妇女MTHFR C677T基因多态性与股骨颈骨密度相关,TT基因型女性具有较低的骨密度,TT基因型可作为预测绝经妇女骨质疏松症的风险因子.%Objective: Osteoporosis is a condition characterized by low BMD and micro - architectural change in bone tissue. The risk of osteoporosis is partly determined by genetic factors. Some studies investigated the role of C677T polymorphism of methylenetetrahydrofolate reductase ( MTHFR) in postmenopausal osteoporosis. However, the relationship between MTHFR polymorphism and BMD is still controversial. So a meta - analysis was performed to evaluate the association of MTHFR and BMD in postmenopausal women. Methods: MEDLINE, Web of Science, Scopus and CNKI were retrieved for all publications relating to MTHFR polymorphism and BMD in postmenopausal women. We performed this meta - analysis involving 5833 subjects. Results: Five eligible studies were selected for meta - analysis. These articles all studied the association of MTHFR polymorphism and the femoral neck and lumbar spine BMD in postmenopausal women. It suggested that the postmenopausal women with the TT genotype had lower femoral neck BMD than that of the CC/CT genotype women, and the weighted mean difference (WMD) was -0.01 g/cm2[95% confidence interval (CI): -0.01, -0.01, P<0.0001]. Individuals with TT genotype tended to have somewhat lower BMD of lumbar spine, but the difference was not statistically significant. In random effects model, the WMD between the TT and TC/CC genotypes was -0.01 g/cm2(95% C1 -0.04, 0.01, P = 0.32). Conclusions : The C677T polymorphism of the MTHFR gene is associated with BMD of femoral neck in postmenopausal women. The women with the TT genotype of MTHFR gene have lower BMD, suggesting that TT genotype may serve as a risk factor for postmenopausal osteoporosis.